The Global Reach Of Stem Cell Research Patents

Law360, New York (February 1, 2012, 1:33 PM EST) -- The Court of Justice of the European Union (CJEU)[1] has ruled in Brustle v. Greenpeace that processes involving the derivation of stem cells from a human embryo at the blastocyst stage, entailing the destruction of that embryo, cannot be patented.

This article briefly sums up the CJEU decision of October 2011 and compares the different approaches to patentability of stem cells being taken in Europe and the U.S. We also consider the implications of these differences on the future of research involving human embryonic stem cells...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.